How Many Doctors Have Been Warned About Buying Fake Cancer Meds? Interchange 2014

Black Market Cancer Drugs Interchange 2014

Black market cancer medication exploded onto the front pages in 2012 when counterfeit Avastin was found in doctors’ offices throughout the nation. Since 2007, more than 1,000 doctors

have received warning letters from the FDA for doing business with known purveyors of counterfeit cancer medication.

SAFEMEDICINES’ report, Black Market Cancer Drug Cases 2007-2013 describes the growing infiltration of fake and misbranded cancer medications into the United States.

 


AGENDA  Sponsor stack

7:30 a.m. – 8:30 a.m. Pre-conference breakfast, sponsor table browsing and networking.

8:30 a.m. – 8:40 a.m. Conference opener

  • Introduction – Scott LaGanga, Executive Director Partnership for Safe Medicines; Senior Vice President, Public Affairs – Advocacy, Pharmaceutical Research and Manufacturers of America (PhRMA)

8:40 a.m. – 9:10 a.m. Original Research

  • Dr. Marv Shepherd, Director, Center for Pharmacoeconomic Studies
    College of Pharmacy, University of Texas-Austin
  • After Counterfeit Avastin – What have we learned and what can be done
    Dr. Tim Mackey, Assistant Professor, UCSD School of Medicine
    Associate Director, MAS Program in Health Policy and Law
    Director, Global Health Policy Institute

9:10 a.m. – 10:25 a.m. Panel 1: The Global Perspective – What are the global issues of counterfeit, substandard and non-FDA approved drugs that impact American patients?

  • Moderator: Tom Kubic, President and CEO, Pharmaceutical Security Institute

Panelists:

  • Gillian Buckley, Program Officer, Institute of Medicine
  • Jim Dahl, Assistant Director of the FDA’s Office of Criminal Investigations (OCI) (retired)
  • Samantha Gompel, IPM Communications Manager at the World Customs Organization
  • Philip Walsky, Acting Director, FDA-OCI

10:25 a.m. – 10:40 a.m. Networking Break

10:40 a.m. – 11.55 a.m. Panel 2: Patient safety and criminal prosecutions in the U.S.

  • Moderator: Linda I. Marks, Senior Litigation Counsel, Consumer Protection Branch, Department of Justice

Panelists:

  • Lindsay Androski Kelly, Assistant U.S. Attorney
  • Jaime Pena, Assistant U.S. Attorney
  • TBD

11:55 a.m. – 12:55 p.m. Networking Lunch

12:55 p.m. – 1:05 p.m. Pre-Panel Presentation (downstairs) PSM India

  • Bejon Misra, Founder, Partnership for Safe Medicines India
  • Madame LiHong Gu, Partnership for Safe Medicines China

1:05 p.m. – 2:20 p.m. Panel 3: The Impacts of Fake Online Pharmacies on Patient Safety

  • Moderator: Special Agent Daniel Burke, Senior Operations Manager in Charge of Cybercrime Investigations for the Office of Criminal Investigations

Panelists:

  • Libby Baney, Executive Director, Alliance for Safe Online Pharmacies
  • Todd Brown, Executive Director, Massachusetts Independent Pharmacists Association
  • Kenneth “Mac” McCall, President, Maine Pharmacy Association

2:20 p.m. – 2:50 p.m. Panel 4: How the Black Market Impacts Patients

  • Moderator: Jim Dahl

Panelists:

  • Kimberly New, National Association of Drug Diversion Investigators
  • Gaurvika Nayyar, Program Manager for Asia at United States Pharmacopeia’s Promoting the Quality of Medicines Program
  • Eric Sampson, Advisor to the CDC Foundation

2:50 p.m. – 3:05 p.m. Mid Afternoon Break

3:05 p.m. – 3:35 p.m. Keynote

  • Jim Hood, Attorney General, State of Mississippi

3:35 p.m. – 4:15 p.m. Keynote

  • Howard Sklamberg, FDA Deputy Commissioner

4:15 p.m. – 4:17 p.m. Closing Remarks, Marv Shepherd

4:17 p.m. – 5:15 p.m. Reception